At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
A-101 25% +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Vehicle-Controlled, Within-Subject, Comparison Study of the Safety, Tolerability, And Effectiveness of A-101 Topical Solution in Subjects With Seborrheic Keratosis
In Brief
A Phase 2 clinical trial evaluating A-101 25%, A-101 32.5%, and 2 other interventions for Seborrheic Keratosis (SK). Completed, enrolled 35 participants across 1 site.
Detailed Summary
Evaluate the safety, tolerability of A-101 when applied to seborrheic keratosis lesions on the back of subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeborrheic Keratosis (SK)
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartOct 2013
First PostedNov 2013
Primary CompletionFeb 2014
TodayJul 2026
First PostedNov 19, 2013
Enrollment StartOct 22, 2013
Primary CompletionFeb 25, 2014
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 12.6 years ago
Interventions
A-101 25%drug
Low Dose Concentration of A-101 applied to one of 4 Target Lesions
A-101 32.5%drug
Mid Dose Concentration of A-101 applied to one of 4 Target Lesions
A-101 40%drug
High Dose Concentration A-101 applied to one of 4 Target Lesions
A-101 Vehicledrug
Placebo applied to one of 4 Target Lesions